| Cash Flow | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
| Net income | -232,986 | -32,860 | 100,463 | NaN |
| Net loss | NaN | NaN | NaN | -100,361 |
| Gain on disposition of vehicle | 0 | 7,000 | NaN | NaN |
| Stock-based compensation | 8,619 | 8,619 | 4,399 | 30,680 |
| Depreciation and amortization | 13,640 | 14,796 | 15,817 | 44,049 |
| Amortization of operating lease right-of-use | 0 | 29,388 | 43,359 | 125,850 |
| Reinvested interests | -544 | 83,346 | -148,220 | 185,746 |
| Decrease (increase) in accounts receivable | 77,977 | 277,116 | 347,839 | -551,482 |
| Decrease (increase) in prepaids and other assets | NaN | NaN | -308,312 | NaN |
| Increase in other assets | -3,392 | -67,619 | NaN | 27,903 |
| Decrease in liabilities | -546,515 | -148,056 | 79,597 | -932,603 |
| Net cash used in operating activities | -365,311 | -390,139 | 279,666 | -494,552 |
| Acquisition of property and equipment | 2,321 | 2,411 | 350 | 6,294 |
| Proceeds from sale of vehicle | 0 | 7,000 | NaN | NaN |
| Marketable securities settlement (investment), net | -1,884,810 | 2,762,155 | -2,063,179 | 603,432 |
| Net cash provided by (used in) investing activities | -1,887,131 | 2,766,744 | -856,665 | -609,726 |
| Repurchase of common stock | 709 | 1,681 | 9,202 | 22,241 |
| Cash dividends paid to shareholders | 1,717,627 | NaN | 0 | 1,719,918 |
| Net cash used in financing activities | -1,718,336 | -1,681 | -9,202 | -1,742,159 |
| Effect of exchange rate changes on cash | -1,366 | 9,482 | 7,661 | 36,833 |
| Net decrease in cash and cash equivalents | -3,972,144 | 2,384,406 | -578,540 | -2,809,604 |
| Cash and cash equivalents - beginning of period | 5,763,618 | 3,379,212 | 6,767,356 | NaN |
| Cash and cash equivalents - end of period | 1,791,474 | 5,763,618 | 3,379,212 | NaN |
Pharma-Bio Serv, Inc. (PBSV)
Pharma-Bio Serv, Inc. (PBSV)